Effects of PON1 Gene Promoter DNA Methylation and Genetic Variations on the Clinical Outcomes of Dual Antiplatelet Therapy for Patients Undergoing Percutaneous Coronary Intervention.
Shilong ZhongXi-Yong YuHong WuYan-Hong KangWan-Ping ZhongLi-Yun CaiMeng-Zhen ZhangJi-Yan ChenLi-Ping MaiQing-Shan DingMin YangShi-Long ZhongPublished in: Clinical pharmacokinetics (2019)
Hypomethylation of CpGs in the PON1 promoter may be a weak, albeit statistically significant, risk factor of bleeding after dual antiplatelet therapy. Further large-scale studies are needed to verify our results.
Keyphrases
- antiplatelet therapy
- dna methylation
- percutaneous coronary intervention
- genome wide
- acute coronary syndrome
- copy number
- st segment elevation myocardial infarction
- patients undergoing
- gene expression
- st elevation myocardial infarction
- acute myocardial infarction
- coronary artery disease
- atrial fibrillation
- coronary artery bypass grafting
- risk factors
- transcription factor